Inhibitors of key molecules in BCR signalling such as PI3Kδ inhibitors (idelalisib) or Bruton tyrosine kinase-BTK inhibitors (ibrutinib) have been recently approved by the FDA for the treatment of CLL or MCL39 and others are under investigation40. Here, BTK is linked to B-cell chronic lymphocytic leukemia.